Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Compared with participants without PHPT, those with PHPT were younger and had higher total calcium, PTH and alkaline phosphatase; lower phosphate and 25-hydroxyvitamin D; and more frequent nephrolithiasis (Table 3; Supplementary Tables S1 and S2).

Source: 3.1. Cohort Characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We conducted a multicentre retrospective cohort study across three campuses (Main, East and Caotang) of Sichuan Provincial People’s Hospital.

Source: Methods.

Participants were excluded if they were pregnant or lactating (n = 13); had a malignancy, severe acute or chronic infection, an established haematological disorder or severe liver disease (n = 315); had undergone previous parathyroidectomy (n = 98); had more than 20% of the 22 collected clinical variables missing (n = 875); had received calcimimetics, thiazide diuretics, glucocorticoids or lithium within the preceding three months (n = 277); or had received bone-forming or antiresorptive agents, including teriparatide and bisphosphonates, within the preceding year (n = 923).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

A Two-Stage Prediction Strategy for Primary Hyperparathyroidism

Cohort study · Diagnostics · 2026

Original publication title

A Two-Stage Prediction Strategy for Primary Hyperparathyroidism

Ruisi Chen; Min Ren; Jingyan Chen; Pin Wang

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background:

Primary hyperparathyroidism parathyroid hormone (PTH) hypersecretion is difficult to recognise when calcium is normal and difficult to distinguish from secondary hyperparathyroidism once PTH is found to be elevated. These are separate problems arising at separate points in care. We developed and evaluated two interpretable models corresponding to these decision points using an internal: external validation design.

Methods:

We analysed 2788 adults undergoing PTH testing across three campuses of one hospital (development n = 1843; internal: external validation n = 445 and n = 500); those with an estimated glomerular filtration rate below 30 mL/min/1.73 m2 were excluded. PHPT was adjudicated in 504 (18.1%) by two endocrinologists using biochemistry, imaging and histopathology. Model 1, for use before PTH is measured, comprised total calcium, ln(alkaline phosphatase) and age. Model 2, developed in the Main campus subgroup with PTH above the reference limit (>65 pg/mL, n = 429 of 623), comprised ln(PTH), total calcium and phosphate.

Results:

Model 1 achieved AUCs of 0.920 in the development cohort and 0.882 to 0.908 in the validation cohorts; because serum calcium contributed to the outcome definition, these estimates reflect agreement with the reference standard rather than independent diagnostic accuracy. Among participants with elevated PTH, Model 2 achieved an AUC of 0.904 in the development cohort and 0.892 in the pooled validation cohort compared with 0.803 and 0.791 for PTH alone, respectively. In the normocalcaemic subgroup, Model 2 achieved an AUC of 0.790 compared with 0.699 for PTH alone. Applied sequentially, the models referred 18.0 to 26.1% of participants while capturing 78.1 to 85.0% of PHPT cases and identified a second-stage subgroup with an observed PHPT prevalence of 93.1 to 95.1%.

Conclusions:

This two-stage strategy may support further testing and referral for PHPT using routinely available measurements. Prospective validation in broader clinical populations is required before clinical implementation.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Primary hyperparathyroidism parathyroid hormone (PTH) hypersecretion is difficult to recognise when calcium is normal and difficult to distinguish from secondary hyperparathyroidism once PTH is found to be elevated. These are separate problems arising at separate points in care. We developed and evaluated two interpretable models corresponding to these decision points using an internal: external validation design.

Source: Background:

Abstract: Results

Model 1 achieved AUCs of 0.920 in the development cohort and 0.882 to 0.908 in the validation cohorts; because serum calcium contributed to the outcome definition, these estimates reflect agreement with the reference standard rather than independent diagnostic accuracy. Among participants with elevated PTH, Model 2 achieved an AUC of 0.904 in the development cohort and 0.892 in the pooled validation cohort compared with 0.803 and 0.791 for PTH alone, respectively. In the normocalcaemic subgroup, Model 2 achieved an AUC of 0.790 compared with 0.699 for PTH alone. Applied sequentially, the models referred 18.0 to 26.1% of participants while capturing 78.1 to 85.0% of PHPT cases and identified a second-stage subgroup with an observed PHPT prevalence of 93.1 to 95.1%.

Source: Results:

Abstract: Conclusions

This two-stage strategy may support further testing and referral for PHPT using routinely available measurements. Prospective validation in broader clinical populations is required before clinical implementation.

Source: Conclusions:
Authors’ abstract

Background:

Primary hyperparathyroidism parathyroid hormone (PTH) hypersecretion is difficult to recognise when calcium is normal and difficult to distinguish from secondary hyperparathyroidism once PTH is found to be elevated. These are separate problems arising at separate points in care. We developed and evaluated two interpretable models corresponding to these decision points using an internal: external validation design.

Methods:

We analysed 2788 adults undergoing PTH testing across three campuses of one hospital (development n = 1843; internal: external validation n = 445 and n = 500); those with an estimated glomerular filtration rate below 30 mL/min/1.73 m2 were excluded. PHPT was adjudicated in 504 (18.1%) by two endocrinologists using biochemistry, imaging and histopathology. Model 1, for use before PTH is measured, comprised total calcium, ln(alkaline phosphatase) and age. Model 2, developed in the Main campus subgroup with PTH above the reference limit (>65 pg/mL, n = 429 of 623), comprised ln(PTH), total calcium and phosphate.

Results:

Model 1 achieved AUCs of 0.920 in the development cohort and 0.882 to 0.908 in the validation cohorts; because serum calcium contributed to the outcome definition, these estimates reflect agreement with the reference standard rather than independent diagnostic accuracy. Among participants with elevated PTH, Model 2 achieved an AUC of 0.904 in the development cohort and 0.892 in the pooled validation cohort compared with 0.803 and 0.791 for PTH alone, respectively. In the normocalcaemic subgroup, Model 2 achieved an AUC of 0.790 compared with 0.699 for PTH alone. Applied sequentially, the models referred 18.0 to 26.1% of participants while capturing 78.1 to 85.0% of PHPT cases and identified a second-stage subgroup with an observed PHPT prevalence of 93.1 to 95.1%.

Conclusions:

This two-stage strategy may support further testing and referral for PHPT using routinely available measurements. Prospective validation in broader clinical populations is required before clinical implementation.

Publication and source details

Original title: A Two-Stage Prediction Strategy for Primary Hyperparathyroidism

Ruisi Chen; Min Ren; Jingyan Chen; Pin Wang

Diagnostics · 2026

* Correspondence: chenjingyan@med.uestc.edu.cn (J.C.); wangpin@med.uestc.edu.cn (P.W.); Tel.: +86-17708130069 (J.C.); +86-13688173316 (P.W.); Fax: +86-28-87393999 (J.C. & P.W.)
†

These authors contributed equally to this work.

© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:35:52.925161+00:00

DOI: 10.3390/diagnostics16193200 · PMC13663940